Gulbrandsen Technologies Achieves Milestone with Successful filing of US DMF for Sucralfate API
We are proud to announce a significant milestone for Gulbrandsen Technologies’ Life Sciences business unit—the successful filing of the US Drug Master File (DMF) for Sucralfate API, a trusted anti-ulcer active substance. This achievement underscores our commitment to regulatory excellence and expands our opportunities in the US pharmaceutical market. A Time-Tested Anti-Ulcer Medication Sucralfate has…
Read MoreGulbrandsen Technologies enters vaccine market with aluminum-based adjuvants
Gulbrandsen Technologies is currently building a new facility for the production of aluminum-based adjuvants at its current site in Gujarat, India – strictly compliant with cGMP regulations for the manufacture of sterile vaccine adjuvants, targeting both human and veterinary applications. According to company president, Vikram Singhal, Gulbrandsen Technologies has been making the world a better…
Read MoreBringing Critical, New Products to Market: Gulbrandsen Technologies Invests in New Sucralfate Plant in Gujarat, India
Q&A with Pritesh Chauhan, Deputy General Manager of New Business Development at Gulbrandsen Technologies
Read More